Technology area: Biotechnology & Pharmaceuticals
39 pending office actions • 28 art units • 38 examiners • 0 of 39 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Ucl Business Ltd. has 38 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 37 distinct examiners and 27 distinct art units, indicating broad examiner distribution with recurring activity across multiple technical groups.
ABBOTT, KODYE LEE is the busiest examiner, with 2 pending matters. Counsel should use centralized review for consistent biotechnology claim and disclosure positions while preserving examiner-specific response analysis.
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (10%) |
| §103 only | 12 (31%) |
| §112 only | 5 (13%) |
| Double-patenting only | 1 (3%) |
| Double-patenting + other | 4 (10%) |
| Multi-statute (no §101) | 13 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBOTT, KODYE LEE | 2 | 54.5% | +71.4% |
| LEONG, NATHAN T | 1 | 71.4% | +23.9% |
| MAHROUKA, WASSIM | 1 | 86.2% | +6.2% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| YU, TIAN NMN | 1 | 55.6% | +19.3% |
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| HOCKER, JOHN PAUL | 1 | 55.9% | +30.8% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683412 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793221 | DRUG ELUTING BIOMATERIALS | PRAGANI, RAJAN | 12d |
| 18009936 | METHODS FOR DETECTING AND PREDICTING BREAST CANCER | BAUSCH, SARAE L | 27d |
| 19404375 | METHOD OF DEPOSITING A SUBSTANCE ON A SUBSTRATE | LEONG, NATHAN T | — |
| 19101219 | Probe Pose Determination | MAHROUKA, WASSIM | — |
| 18701115 | GUIDE RNA AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | YU, TIAN NMN | — |
| 18579635 | METHODS AND REAGENTS FOR THE DETECTION OF ANALYTES | LY, KRISTINA ELISABETH | — |
| 18564461 | METHODS AND APPARATUS FOR OPTICAL FIBRE DESIGN AND PRODUCTION | HOCKER, JOHN PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18505809 | COMPOSITIONS FOR THE TREATMENT OF A DISEASE OF THE URINARY TRACT AND TREATMENT OF A DISEASE INVOLVING THE INTRACELLULAR DELIVERY OF THE PARTICLE OR A MEDICAMENT CONTAINED THEREIN | KIM, DANIELLE A | 1d overdue |
| 19404375 | METHOD OF DEPOSITING A SUBSTANCE ON A SUBSTRATE | LEONG, NATHAN T | — |
| 18792799 | METHOD FOR ENHANCING THE SUPPRESSIVE PROPERTIES OF TREG CELLS | WESTON, ALYSSA G | — |
| 18701115 | GUIDE RNA AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | YU, TIAN NMN | — |
| 18579635 | METHODS AND REAGENTS FOR THE DETECTION OF ANALYTES | LY, KRISTINA ELISABETH | — |
| 18564461 | METHODS AND APPARATUS FOR OPTICAL FIBRE DESIGN AND PRODUCTION | HOCKER, JOHN PAUL | — |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 4 |
| 1633 | 3 |
| 1637 | 2 |
| 1636 | 2 |
| 3797 | 2 |
| 1634 | 2 |
| 1631 | 2 |
| 1718 | 1 |
| 2665 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19404375 | METHOD OF DEPOSITING A SUBSTANCE ON A SUBSTRATE | LEONG, NATHAN T | 1718 | §102§103 | Non-Final OA | — | Pending | Dec 01, 2025 |
| 19101219 | Probe Pose Determination | MAHROUKA, WASSIM | 2665 | §101§103 | Non-Final OA | — | Pending | Feb 04, 2025 |
| 18792799 | METHOD FOR ENHANCING THE SUPPRESSIVE PROPERTIES OF TREG CELLS | WESTON, ALYSSA G | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18701115 | GUIDE RNA AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | YU, TIAN NMN | 1681 | §102§103§112 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18683412 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | HABTE, KAHSAY | 1624 | §112Other | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18579635 | METHODS AND REAGENTS FOR THE DETECTION OF ANALYTES | LY, KRISTINA ELISABETH | 1671 | §102§103§112 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18564461 | METHODS AND APPARATUS FOR OPTICAL FIBRE DESIGN AND PRODUCTION | HOCKER, JOHN PAUL | — | §101§103 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18505809 | COMPOSITIONS FOR THE TREATMENT OF A DISEASE OF THE URINARY TRACT AND TREATMENT OF A DISEASE INVOLVING THE INTRACELLULAR DELIVERY OF THE PARTICLE OR A MEDICAMENT CONTAINED THEREIN | KIM, DANIELLE A | 1613 | §103 | Final Rejection | 1d overdue | Pending | Nov 09, 2023 |
| 18559778 | SYNTHETIC RECEPTORS | ABUZEINEH, HANAN ISAM | 1633 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18552977 | USE OF MICROVESICLES FOR BENIGN COLORECTAL POLYPS AND COLORECTAL CANCER SCREENING | MUI, CHRISTINE T | 1797 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18550739 | CD160 Binding Domain | NICKOL, GARY B | 1643 | §112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18282061 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY | BURKHART, MICHAEL D | 1638 | §103 | Final Rejection | 3d overdue | Pending | Sep 14, 2023 |
| 18261411 | SUBJECT POSITIONING | BUI PHO, PASCAL M | 3798 | §103 | Final Rejection | — | Pending | Jul 13, 2023 |
| 18269141 | TREATMENT FOR LYSINE DEGRADATION-ASSOCIATED DISORDERS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18258414 | A SYSTEM FOR POSITIONING A MEDICAL TOOL | ASGHAR, AMINAH | 3797 | §103 | Final Rejection | 86d overdue | Pending | Jun 20, 2023 |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18255444 | RETROVIRAL VECTORS | ABBOTT, KODYE LEE | 1634 | §103 | Final Rejection | — | Pending | Jun 01, 2023 |
| 17915043 | ACTIVITY-DEPENDENT GENE THERAPY FOR NEUROLOGICAL DISORDERS | GROOMS, TIFFANY NICOLE | 1637 | §102§103§112DP | Non-Final OA | — | Pending | May 22, 2023 |
| 18194235 | ELECTROCARDIOGRAPHIC IMAGING SYSTEM AND METHOD | BROWN, HELENE CATHERINE | 3797 | §103 | Final Rejection | 28d overdue | Pending | Mar 31, 2023 |
| 18042899 | PRODUCTION OF INORGANIC SALTS | ZIMMER, ANTHONY J | 1736 | §103 | Final Rejection | 44d overdue | Pending | Feb 24, 2023 |
| 18011583 | THERAPEUTICS FOR THE TREATMENT OF FSHD | SAMSELL, RILLA MARIE | 1626 | §102§112DP | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18009945 | METHODS FOR DETECTING AND PREDICTING CANCER AND/OR CIN3 | KENNEDY, SARAH JANE | 1682 | DP | Final Rejection | 72d overdue | Pending | Dec 12, 2022 |
| 18009936 | METHODS FOR DETECTING AND PREDICTING BREAST CANCER | BAUSCH, SARAE L | 1699 | §101§102§112 | Final Rejection | 27d | Pending | Dec 12, 2022 |
| 18047199 | GENE THERAPY FOR BARDET-BIEDL SYNDROME | MONTANARI, DAVID A | 1632 | §102§103 | Non-Final OA | — | Pending | Oct 17, 2022 |
| 17904388 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | MCMILLIAN, KARA RENITA | 1623 | §102§112Other | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17819757 | END-EFFECTOR FOR ENDOSCOPIC SURGICAL INSTRUMENT | MULLINS, JESSICA LYNN | 3792 | §102§103 | Non-Final OA | — | Pending | Aug 15, 2022 |
| 17798796 | GENE THERAPY | SINGH, ANOOP KUMAR | 1632 | §112 | Non-Final OA | — | Pending | Aug 10, 2022 |
| 17759222 | ENGINEERED IMMUNE CELLS | GODDARD, LAURA B | 1642 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17793221 | DRUG ELUTING BIOMATERIALS | PRAGANI, RAJAN | 1614 | §102§103§112 | Final Rejection | 12d | Pending | Jul 15, 2022 |
| 17784836 | TIME-RESOLVED METHOD OF PROTEIN ANALYSIS | GZYBOWSKI, MICHAEL STANLEY | 1798 | §103 | Non-Final OA | — | Pending | Jun 13, 2022 |
| 17783167 | GENE THERAPY COMPOSITION AND TREATMENT FOR MYH7-LINKED CARDIOMYOPATHY | MOLOYE, TITILAYO | 1632 | §112 | Final Rejection | 16d | Pending | Jun 07, 2022 |
| 17780786 | TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION | INAM, SAHAR | 1633 | §112 | Final Rejection | — | Pending | May 27, 2022 |
| 17775172 | Extracellular Matrix Gels, and Organoid Cultures Comprising the Same | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | 31d overdue | Pending | May 06, 2022 |
| 17773103 | METHOD FOR THE PRODUCTION OF MÜLLER CELLS AND CELL PRODUCT | ZHU, JIANJIAN | 1631 | §103§112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17761677 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRYTHMOGENIC CARDIOMYOPATHY | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Final Rejection | 19d overdue | Pending | Mar 18, 2022 |
| 17633593 | Antisense oligonucleotides rescue aberrant splicing of ABCA4 | RAVINDRA, KRISHNA NUGGEHALLI | 1636 | §103§112 | Final Rejection | — | Pending | Feb 08, 2022 |
| 17044558 | DRAINAGE DEVICE AND METHODS | LEVY, BRANDON WILLIAM | 3781 | §103 | Final Rejection | 27d | Pending | Oct 01, 2020 |
| 17904393 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 | WELLS, LAUREN QUINLAN | 1622 | §112DP | Non-Final OA | 87d overdue | Pending | Aug 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUcl Business Ltd. has 39 pending office actions as of October 2026, spread across 28 art units and 38 examiners.
Kodye Lee Abbott has the most, with 2 of Ucl Business Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
